Ankur Drugs and Pharma Ltd., one of the top pharmaceutical companies, has posted substantial turnover for the first quarter of the 2009 fiscal. Net Income rose 70.23% to Rs. 231.14 crore, up from Rs. 135.78 crores in the last fiscal. The company posted a PAT of Rs. 21.58 crores, a hop of 75% over Rs.12.31 crores for the same quarter last fiscal.

Announcing the results, Mr. Purnandu Jain, Chairman & Managing Director of Ankur Drugs and Pharma Ltd. said, “We are quite pleased with our present turnover and going forward, we hope to maintain the growth pitch.”

Mr. Jayesh Trivedi has joined the Company as head of Regulatory Affairs and International Operations. Mr. Trivedi has enviable experience in Contract Research & Manufacturing Services (CRAMS). Mr. Trivedi’s objective in Ankur is to establish the company as a preferred partner of CRAMS.

- End -

About Ankur Drugs and Pharma Ltd.

A public limited company listed in both the BSE and NSE, Ankur Drugs and Pharma Ltd. is engaged in manufacturing of pharmaceutical formulations for leading Indian companies. Ankur manufactures 400 different formulations for different dosage forms like tablets, capsules, syrups, and liquid orals. Ankur Drugs has emerged as a leading contract manufacturer of formulations.